Solid tumours

Scientist in laboratory
#Cancer research #Crescendo Biologics #Financing #Oncology #Phase I trial #Solid tumours

Crescendo secures $32M to expand Phase Ib trial in solid tumours

Immuno-oncology company Crescendo Biologics has revealed plans to augment the ongoing Phase Ib clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major existing shareholders, including Sofinnova… Read More

#Cancer Research #News

#AI #Cancer #CNS #FDA #Lantern Pharma #Solid tumours

FDA clearance of IND application for solid tumour drug 

Lantern Pharma, an AI company developing targeted and transformative cancer therapies, has received clearance from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumours and central nervous system (CNS) cancers.   The… Read More

#News

#Cancer research #Cancer Research Month #Immuno-oncology #Oncology #Solid tumours

New podcast episode: DDW Highlights, 5 June 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With National Cancer Research Month coming to an end in May and the American Society… Read More

#News

#Cancer research #Cancer Research Month #Immuno-oncology #Oncology #Solid tumours

This week in drug discovery (29 May – 2 June)

News round-up for 29 May – 2 June by DDW Digital Content Editor Diana Spencer. With National Cancer Research Month coming to an end and the American Society of Clinical Oncology Annual Meeting currently taking place in Chicago (2-6 June), it’s been another… Read More

#News

Monoclonal antibodies
#Aulos Bioscience #Cancer research #Immuno-oncology #Monoclonal antibodies #Oncology #Phase I trial #Solid tumours

AI-designed monoclonal antibody ‘redirects’ the immune system

Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. The data indicate that AU-007 is well tolerated in patients with unresectable locally advanced or metastatic cancer and there are early signs of anti-tumour activity. Read More

#Cancer Research #Editor's Choice #News

#Oncology #RNA #Solid tumours

New solid tumour panel could save time and expense 

Integrated DNA Technologies (IDT) has launched a new solution to optimise operational efficiency and the identification of solid cancer tumours.   The IDT Archer FUSIONPlex Core Solid Tumor Panel is a first-line cancer research testing solution that has been expanded and optimised for additional single nucleotide variant (SNV)… Read More

#News

Cancer cells
#AACR 2023 #Cancer research #Oncology #Paediatrics #Phase I trial #Solid tumours

Combo therapy may benefit some paediatric cancer patients

A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in paediatric patients with solid tumours exhibiting DNA replication stress and/or DNA repair deficiencies, according to new data. The results from the Phase I portion of the Phase I/II… Read More

#Cancer Research #News

Tumour microenvironment
#AACR 2023 #Avacta #Cancer research #Oncology #Preclinical development #Solid tumours

Data shows new therapy successfully targets solid tumours

Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. Read More

#Cancer Research #News

Medical research
#Cancer research #Clinical trial #Oncology #Phase I trial #Solid tumours #Totus Medicines

First patient dosed with PI3Kα inhibitor for solid tumours

Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The Totus Accel Platform is designed to be the first biosearch technology that scans, maps, and… Read More

#Cancer Research #News

Cancer patient receives chemotherapy via IV
#Avacta #Cancer research #Clinical trial #Oncology #Phase I trial #Solid tumours

Avacta increases dose of AVA6000 in solid tumours study

Avacta Group has dosed its first patient in the fifth cohort of the first-in-human Phase I trial (ALS-6000-101) of AVA6000 in solid tumours. This follows the approval of an amended clinical trial protocol by the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to allow for… Read More

#Cancer Research #News

Vaccine vial and syringe
#Cancer research #Cancer vaccine #China #Oncology #Solid tumours #Vaccines

Chinese regulator approves personalised cancer vaccine trial

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. This breakthrough marks the first of its kind in China and represents a significant milestone… Read More

#Cancer Research #News

Pancreatic cancer
#Cancer research #Oncology #Pancreatic cancer #Propanc Biopharma #Solid tumours #Spain #Tumour microenvironment (TME)

Proenzyme suppresses TGF-β pathway in pancreatic cancer

A Spanish study has shown that PRP, a mixture of two proenzymes, trypsinogen and chymotrypsinogen, suppresses the TGF-β pathway and the tumour microenvironment in pancreatic cancer. The study was co-led by Belén Toledo Cutillas, at the laboratory of Professor Macarena Perán, University of Jaén, Granada, Spain. Read More

#Cancer Research #Editor's Choice #News

#Biotechnology #Cancer research #Clinical research #Innovation passport #MHRA #Solid tumours #T-Cells

Uveal melanoma drug granted MHRA Innovation Passport 

iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, has been awarded the innovative medicine designation, the Innovation Passport, for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA).  Roginolisib is a first-in-class, non-ATP-competitive,… Read More

#News

#Breast cancer #Cancer research #CAR-T #Drug discovery #Immunotherapy #Oncology #Pancreatic cancer #Prostate cancer #Solid tumours

Latest episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen a number of developments in the treatment of solid tumours… Read More

#News

#Breast cancer #Cancer research #CAR-T #Drug discovery #Immunotherapy #Oncology #Pancreatic cancer #Prostate cancer #Solid tumours

This week in drug discovery (20-24 March)

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer.  This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in… Read More

#News

Haematology
#Biotechnology #Cancer research #Clinical research #Solid tumours #T-Cells

Research reveals the unique biological features of roginolisib 

iOnctura, a clinical stage biotechnology company developing cancer therapies, has published non-clinical research on roginolisib in the AACR journal Cancer Research Communications. Roginolisib is a first-in-class, non-ATP-competitive, allosteric modulator of PI3Kd which prevents tumour proliferation and breaks immune tolerance in patients with solid and haematological… Read More

#Cancer Research #News